Strategic Collaborations Stratatech actively partners with prominent research and medical institutions such as the Armed Forces Institute of Pathology and University of Wisconsin campuses, which opens avenues for joint ventures, research collaborations, and procurement of innovative biotechnological solutions.

Regenerative Innovation Specializing in cell-based therapies for severe burns and skin defects, Stratatech offers cutting-edge regenerative medicine products that appeal to healthcare providers and institutions seeking advanced treatment options, creating potential sales channels in medical device and healthcare markets.

Acquisition Advantage Since its acquisition by Mallinckrodt in 2016, Stratatech benefits from increased resource backing and credibility, making it an attractive partner for organizations looking for innovative regenerative therapies and related biotechnologies.

Growing Market Presence With revenues between 1 to 10 million dollars and a focused biotech niche, Stratatech is positioned as a specialized provider that can expand its client base among hospitals, biotech firms, and government agencies interested in advanced wound healing solutions.

Technological Capabilities Utilizing modern web and analytics tools, Stratatech leverages digital platforms for research, development, and outreach, indicating opportunities to promote their innovation pipelines and secure partnerships through targeted online engagement.